92 results about "Type antigen" patented technology

The present disclosure provides lipid nanoparticle compositions comprising a nucleic acid encoding an RSV antigenic polypeptide. The invention also provides novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).

The invention relates to the field of biological detection, in particular to a broad-spectrum specific antibody and application thereof. The invention provides a monoclonal antibody of human immunodeficiency virus P24 protein. Three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 3, 4 and 5; the three CDR regions of the light chain of the gene respectively have amino acid sequences as shown in SEQ ID NO: 7, 8 and 9. A recombinant human immunodeficiency virus P24 protein is used as an immunogen, a monoclonal antibody capable of simultaneously detecting HIV-1 and HIV-2 core proteins P24 is successfully prepared through different multi-type antigen sequential immunization strategies, an epitope interval of the monoclonal antibody is determined through a recombinant P24 fragment, and a foundation is laid for establishing a detection kit with higher sensitivity.

According to the kit for detecting the helicobacter pylori CagA subtype and the application of the kit, 3E67 and 5T68 monoclonal antibodies are prepared by using CagA dominant immune epitopes, and the monoclonal antibodies are used in a homogeneous chemiluminescence system for the first time to prepare an antigen for detecting the helicobacter pylori CagA subtype. A murine antibody is prepared through immunization of dominant epitopes of helicobacter pylori CagA protein, an antibody pair with good specificity and strong binding force is obtained through an in-vitro screening pairing strategy, and amino acid sequences of a heavy chain variable region and a light chain variable region of the antibody pair are obtained through sequencing. Products for detecting the helicobacter pylori-related CagA antigen are developed on the basis of a chemiluminescence platform, an enzyme-linked immunosorbent assay platform and an immune layer system platform, and the kit has the advantages of high sensitivity, good specificity and rapid detection.

The present invention generally relates to improved protease-activatable antigen-binding molecules. The protease-activatable antigen-binding molecules contain an anti-idiotypic binding portion that reversibly masks the CD3 antigen-binding portion of the molecule. Furthermore, the present invention relates to polynucleotides encoding such protease-activatable T cell binding molecules, as well as vectors and host cells containing such polynucleotides. The present invention further relates to methods for producing the protease-activatable T cell binding molecules of the present invention and methods for using the protease-activatable T cell binding molecules, for example, in the treatment of diseases.

The invention relates to a multi-metal element nano-aluminum adjuvant and a preparation method and application thereof, the nano-aluminum adjuvant is a nano-particle containing an aluminum element and at least one metal element selected from magnesium, zinc and calcium, the nano-particle has a layered crystal structure, and the particle size is distributed in a range of 20-2000 nm. The difunctional nano-aluminum adjuvant has the beneficial effects that the difunctional nano-aluminum adjuvant is simple and convenient in preparation method, definite in component and uniform in particle size, the particle size of the particles can be manually regulated and controlled, and the difunctional nano-aluminum adjuvant can directly promote antigen presenting cells to be mature and activated and carry out MHC-I or II type antigen presentation.

The application provides a PLA2R monoclonal antibody and an ELISA kit comprising the antibody. Specifically, the application provides a monoclonal antibody which specifically binds to PLA2R, wherein the antibody only binds to non-reduced PLA2R antigen with a conformational epitope, does not bind to reduced PLA2R antigen, and does not bind to another antigen THSD7A of primary membranous nephropathy. An ELISA kit prepared based on the antibody can more efficiently and accurately detect primary membranous nephropathy than existing commercial kits.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The application provides an anti-Norovirus GII genotype VP1 antigen monoclonal antibody and an application thereof. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain CDR3 shown in SEQ ID NO. 3, and the light chain variable region comprises a light chain CDR3 shown in SEQ ID NO. 6. The monoclonal antibody is a rabbit-derived monoclonal antibody, the monoclonal antibody has good specificity and high affinity, and solves the problem of a mouse-derived monoclonal antibody in actual application. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody has important application value in the preparation of a product for detecting Norovirus.

Provided is a novel antigen detection method capable of detecting an antigen, as a substance to be detected, by using a signal transmission line for transmitting a high-frequency signal. This antigen detection method for detecting an antigen in a sample comprises: a step in which a sample, containing an antigen reacted with both a primary antibody for fixing the antigen to a carrier and a secondary antibody labelled with magnetic particles, is produced; a step in which the sample is placed close to or in contact with a probe in which a signal transmission line is formed; a step in which a DC magnetic field in a direction along the signal transmission line is applied to the sample by a magnetic field application means; a step in which a high-frequency signal is supplied to the signal transmission line by a signal measurement instrument electrically connected to the signal transmission line; a step in which a signal being transmitted along the signal transmission line in a state in which the DC magnetic field is being applied is measured by the signal measurement instrument over a predetermined frequency band; and a step in which the antigen is detected by an arithmetic processing means on the basis of a signal corresponding to the resonance frequency of ferromagnetic resonance observed in the predetermined frequency band.

The invention discloses an FUT2 high-expression cell strain as well as application and a method of the FUT2 high-expression cell strain in vaccine quality control, and belongs to the technical field of vaccines. The technical problem to be solved is that a simple and easy-to-operate cell model is lacked in the prior art, and the cell model is used for evaluating the effectiveness of NoV vaccines on the cellular level. According to the key points of the technical scheme, the FUT2 high-expression cell strain is provided, the cell strain is an HEK 293T cell strain (HEK 293T-FUT2-EGFP) with EGFP fluorescence for overexpressing human alpha 1, 2-fucosyltransferase 2 (FUT2), and the cell strain stably expresses H, Lewis b and Lewis y type HBGA antigens; meanwhile, an alternative neutralization experiment of the cell level of the norovirus vaccine based on the cell strain is developed, a basis is provided for interaction research of the norovirus and host cells, and the cell strain has high practical application value.

Disclosed is a chemical synthesis method for Pseudomonas aeruginosa O5 serotype O-antigen oligosaccharide, which belongs to the field of chemical synthesis. In the disclosure, O-antigen trisaccharide is constructed with a D-glucuronic acid building block and a D-fucosamine building block, where the stereoselective synthesis of a 1,2-α-cis-glycosidic bond of D-fucosamine depends on remote acyl participation and reagent regulation, and synthesis of two types of 1,2-β-trans-glycosidic bonds of 2,3-diaminomannuronic acids is achieved via SN2 nucleophilic substitution of azido at position C2; and via selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, multifunctional modified O-antigen target trisaccharide is successfully prepared. According to the method in the disclosure, the raw materials are cheap and easily available, and the preparation method is simple and easy to repeat. Therefore, the method has a very good application prospect in developing vaccines against P. aeruginosa.

The invention discloses a GAGE7 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the GAGE7 recombinant antigen is shown as SEQ ID NO.1. Through verification, compared with a wild type GAGE7 antigen, the detection sensitivity of the GAGE7 recombinant antigen is remarkably improved, and meanwhile, the performance of the GAGE7 recombinant antigen is obviously superior to that of a commercially available GAGE7 recombinant antigen. Therefore, the GAGE7 recombinant antigen has a good application prospect in the field of early detection of lung cancer.

The invention relates to the technical field of computational biology, artificial intelligence and drug discovery, in particular to a Foke-Planck equation-based antibody complementary determining region generation method and device.The method comprises the steps of defining a forward stochastic differential process, constructing a neural network-based generation model, and then obtaining an antibody complementary determining region based on de-noising prediction; an implicit fractional field of the generative model is parsed and a Foke-Planck equation (FPE) residual is calculated to train at least one parameter of the generative model for generating the CDR by minimizing a composite loss function containing regularization terms associated with the FPE residual. Therefore, the problems that a correlation generation model objective function only pays attention to local gradients, neglects global physical coherence and excessively depends on a public database with limited data volume and biased distribution, so that chemical unreasonable or energy unstable conformations are generated, and a novel effective combination mode is difficult to generate due to performance reduction when facing novel antigens are solved; the clinical application value is limited.

The invention discloses a preparation method and application of a Taq DNA polymerase monoclonal antibody based on structural domain analysis, which are specifically different from a traditional method using full-length Taq polymerase as an immunogen (the method generally cannot generate a functional blocking antibody due to a hidden epitope which is difficult to approach). According to the invention, by adopting a structure-oriented and domain-specific strategy, the exposure of epitopes related to active sites is remarkably enhanced, and a novel antigen Taq-P protein is developed. Based on the antigen, a high-specificity inhibitory monoclonal antibody is prepared, and the antibody is expected to become a core component of a high-performance hot start PCR reagent. According to the invention, a novel and generalizable mode is established for the development of a core diagnostic reagent, a key raw material is provided for gene detection and molecular diagnosis, and a valuable methodological framework is contributed to the development of propulsor engineering and biotechnology reagents.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

The invention provides a hybridoma cell strain secreting an IgG1 type monoclonal antibody resisting human N-type blood group antigen, the hybridoma cell strain is named as N1C8 and preserved in the China Center for Type Culture Collection on August 7, 2025, and the preservation number is CCTCC NO: C2025231. The invention further provides a monoclonal antibody secreted by the hybridoma cell strain secreting the IgG1 type monoclonal antibody resisting the human N-type blood group antigen and application of the monoclonal antibody. The cell strain is used for preparing a monoclonal antibody for resisting the human N-type blood group antigen, salt and protein are added into the antibody to develop a human N-type blood group antigen detection reagent, and the human N-type blood group antigen detection reagent can be applied to detection of the human N-type blood group antigen, so that a human N-type blood group antigen detection method is more scientific and perfect.

The invention relates to a duck infectious serositis pentavalent inactivated vaccine as well as a preparation method and application thereof. The vaccine is prepared from a duck infectious serositis type 1 antigen, a duck infectious serositis type 2 antigen, a duck infectious serositis type 6 antigen, a duck infectious serositis type 7 antigen and a duck infectious serositis type 10 antigen. The preparation method comprises the following steps: S1, strain screening; step S2, strain culture; step S3, carrying out inactivation treatment; step S4, bacterial liquid mixing; and S5, emulsifying the adjuvant. The duck infectious serositis pentavalent inactivated vaccine has the advantages of prominent broad spectrum, excellent immune effect and high industrial feasibility, can cover more than 90% of epidemic strains, solves the problem of incomplete prevention of the existing vaccine, has protection rates of more than or equal to 90% on the attack of five serotype virulent poison, adopts a fermentation tank for amplification culture in a culture process, has stable bacterial liquid proliferation efficiency, and is suitable for large-scale production. Emulsifying process parameters are clear and suitable for large-scale production.

The present invention provides methods and systems that identify novel antigens that bind to a particular T cell receptor and also validate the immunogenicity of the potential antigens to activate the TCR. The methods allow for development of an exhaustively profile of on-target and off-target reactivity of novel antigens.

The present invention provides novel CD3 antigen binding fragments with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, remaining tumor cell killing and reduced toxicity. The present invention also provides bispecific antigen binding molecules for activating T cells. In addition, the invention further provides methods of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising the above said bispecific antigen binding molecules.

The present application relates to the technical field of tumor immunotherapy. The present application provides a responsive antigen capture nano platform, a preparation method and application thereof. The product of the present application is applied by systemic administration such as intravenous injection; can specifically respond to peroxynitrite in the tumor microenvironment, realize the precise activation of the tumor site; can covalently capture tumor-related antigens through high efficiency, deliver the antigens to antigen presenting cells, so as to enhance the anti-tumor immune response; combined with photodynamic therapy can significantly inhibit tumor growth.

The present invention relates to fibroblast activation protein (FAP)-specific antigen binding molecules, associated fusion proteins and conjugates, and methods of use thereof. In some aspects, the binding molecules comprise a moiety having the form of a shark variable novel antigen receptor (VNAR).

This invention relates to the field of biological detection, and in particular to an IgM antibody for preventing erythrocyte agglutination, its preparation method, and its uses. The IgM antibody for preventing erythrocyte agglutination is obtained by mixing and incubating a natural IgM antibody with DTT. The IgM antibody can be used to prepare products for detecting ABO blood types and products for detecting the expression levels of type A antigen and / or type B antigen. The prepared products can be used for quantitative detection of ABO antigen expression, studying changes in ABO antigen expression levels among different genotypes, and studying diseases related to ABO antigen expression levels.

The present invention provides novel antigen capture nanoparticles (ACNPs) and pharmaceutical formulations containing such ACNPs. Also provided herein are methods for preparing ACNP formulations, and methods for treating a disease, such as cancer, in a subject with ACPN or a pharmaceutical formulation containing ACPN.

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened based on GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3 saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2 I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway and activate CD8 + T cells, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3 saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.

The present disclosure discloses a specific saccharide fragment for development of Vibrio cholerae vaccines, and belongs to the field of medicine. In the present disclosure, a saccharide fragment related to a trisaccharide of V. cholerae O100 serotype O-antigen is chemically synthesized. Combined with a glycan microarray technology, the structure-activity relationship between different saccharide fragments and antigenicity thereof is evaluated at a molecular level. Glycan microarray screening indicates that 3-hydroxybutyryl is an essential structural feature of the O-antigen. A non-reducing end disaccharide carrying 3-hydroxybutyryl is a potential minimal antigenic epitope, and the disaccharide has strong binding capacity to antibodies and a simple structure, and may serves as a specific saccharide fragment for vaccine development. A glycoconjugate vaccine designed based on the specific saccharide fragment may solve the challenges of difficulty in culturing pathogenic bacteria and heterogeneity of saccharide antigens in naturally extracted polysaccharide vaccines. The present disclosure has bright application prospects in the development of glycoconjugate V. cholerae vaccine, infection detection, and new drug development.

This document discloses antibodies targeting CD40 and their uses. It also discloses novel antigen-binding proteins capable of specifically binding to CD40 and their antigen-binding fragments. Furthermore, this document discloses fusion proteins comprising a first domain activating antigen-presenting cells (APCs) (e.g., dendritic cells) and a second domain activating immune effector cells (e.g., T cells), wherein the first domain comprises the antigen-binding protein or its antigen-binding fragment that specifically binds to CD40 disclosed herein.

The invention relates to a blood group antigen detection test strip. The blood group antigen detection test strip comprises a core body, the core body comprises a porous hydrophilic film and a water absorption layer, the porous hydrophilic film is provided with a circular sample introduction area, the diameter of the sample introduction area is 5-10mm, an anti-A monoclonal antibody, an anti-B monoclonal antibody and an anti-D monoclonal antibody are combined in the sample introduction area through sample application treatment, and the diameter of the anti-A monoclonal antibody, the diameter of the anti-B monoclonal antibody and the diameter of the anti-D monoclonal antibody are 5-10mm. The water absorption layer is compounded on the upper surface of the porous hydrophilic film. Solid-phase monoclonal antibodies aiming at different blood group antigens are coated in the sample introduction area in a spotting manner, when vein whole blood or fingertip blood samples are dropwise added into the sample introduction area, the solid-phase monoclonal antibodies can be combined with corresponding antigens in blood to form red indication points, and detection results are quickly displayed. And the rest red blood cells which are not agglutinated can penetrate through the porous hydrophilic film.